Table of Content

1. Product Overview
2. Research Methodology
3. Impact of COVID-19 on India Anti-Fungal Drugs Market
4. Executive Summary
5. Voice of Customers
5.1. Brand Awareness
5.2. Factors Driving India Anti-Fungal Drugs Market
5.3. Unmet Needs and Challenges
6. India Anti-Fungal Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Others)
6.2.2. By Indication (Candidiasis, Aspergillosis, Dermatophytosis, Mucormycosis, Others)
6.2.3. By Infection Type (Superficial Fungal Infection, Systemic Fungal Infection)
6.2.4. By Route of Administration (Parenteral, Topical, Oral, Others)
6.2.5. By End-User (Homecare, Hospitals, Clinics, Others)
6.2.6. By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy)
6.2.7. By Company (FY2021)
6.2.8. By Region
6.3. Product Market Map
7. Azoles Anti-Fungal Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Indication
7.2.2. By Infection Type
7.2.3. By Route of Administration
7.2.4. By End User
7.2.5. By Distribution Channel
8. Echinocandins Anti-Fungal Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Indication
8.2.2. By Infection Type
8.2.3. By Route of Administration
8.2.4. By End User
8.2.5. By Distribution Channel
9. Polyenes Anti-Fungal Drugs Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Indication
9.2.2. By Infection Type
9.2.3. By Route of Administration
9.2.4. By End User
9.2.5. By Distribution Channel
10. Allylamines Anti-Fungal Drugs Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Indication
10.2.2. By Infection Type
10.2.3. By Route of Administration
10.2.4. By End User
10.2.5. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
13. Policy & Regulatory Landscape
14. India Economic Profile
15. Competitive Landscape
15.1. Company Profiles
15.1.1. Pfizer India Ltd.
15.1.2. Cipla Ltd.
15.1.3. Glenmark Pharmaceuticals Ltd.
15.1.4. Sun Pharmaceuticals Industries Ltd.
15.1.5. Dr. Reddy’s Laboratories Ltd.
15.1.6. Viatris Inc. (Mylan NV)
15.1.7. Lupin Ltd.
15.1.8. Zydus Cadila Ltd.
15.1.9. Novartis India Ltd.
15.1.10. Torrent Pharmaceuticals Ltd.
15.1.11. Teva Pharmaceutical Industries Ltd
15.1.12. Janssen Pharmaceuticals Inc. (Johnson & Johnson)
15.1.13. Abbott Laboratories Ltd.
15.1.14. GlaxoSmithKline Plc
15.1.15. Bayer AG
15.1.16. Dabur India Ltd
15.1.17. Bharat Serums & Vaccines Ltd
15.1.18. BDR Pharmaceuticals Internationals Pvt. Ltd.
15.1.19. Lifecare Innovations Pvt. Ltd.
15.1.20. Mankind Pharma Ltd
16. Strategic Recommendations
17. About Us & Disclaimer



List of Figures

Figure 1: India Anti-Fungal Drugs Market Size, By Value (USD Million), FY2017–FY2027F
Figure 2: India Anti-Fungal Drugs Market Share, By Drug Class, By Value, FY2017– FY2027F
Figure 3: India Anti-Fungal Drugs Market Share, By Indication, By Value, FY2017–FY2027F
Figure 4: India Anti-Fungal Drugs Market Share, By Infection Type, By Value, FY2017–FY2027F
Figure 5: India Anti-Fungal Drugs Market Share, By Route of Administration, By Value, FY2017–FY2027F
Figure 6: India Anti-Fungal Drugs Market Share, By End-User, By Value, FY2017–FY2027F
Figure 7: India Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, FY2017–FY2027F
Figure 8: India Anti-Fungal Drugs Market Share, By Company, By Value, FY2017–FY2027F
Figure 9: India Anti-Fungal Drugs Market Share, By Region, By Value, FY2017–FY2027F
Figure 10: India Anti-Fungal Drugs Market Product Market Map, By Type, By Value, FY2017–FY2027F
Figure 11: Azoles Anti-Fungal Drugs Market Size, By Value (USD Million), FY2017–FY2027F
Figure 12: Azoles Anti-Fungal Drugs Market Share, By Indication, By Value, FY2017–FY2027F
Figure 13: Azoles Anti-Fungal Drugs Market Share, By Infection Type, By Value, FY2017–FY2027F
Figure 14: Azoles Anti-Fungal Drugs Market Share, By Route of Administration, By Value, FY2017–FY2027F
Figure 15: Azoles Anti-Fungal Drugs Market Share, By End-User, By Value, FY2017–FY2027F
Figure 16: Azoles Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, FY2017–FY2027F
Figure 17: Echinocandins Anti-Fungal Drugs Market Size, By Value (USD Million), FY2017–FY2027F
Figure 18: Echinocandins Anti-Fungal Drugs Market Share, By Indication, By Value, FY2017–FY2027F
Figure 19: Echinocandins Anti-Fungal Drugs Market Share, By Infection Type, By Value, FY2017–FY2027F
Figure 20: Echinocandins Anti-Fungal Drugs Market Share, By Route of Administration, By Value, FY2017–FY2027F
Figure 21: Echinocandins Anti-Fungal Drugs Market Share, By End-User, By Value, FY2017–FY2027F
Figure 22: Echinocandins Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, FY2017–FY2027F
Figure 23: Polyenes Anti-Fungal Drugs Market Size, By Value (USD Million), FY2017–FY2027F
Figure 24: Polyenes Anti-Fungal Drugs Market Share, By Indication, By Value, FY2017–FY2027F
Figure 25: Polyenes Anti-Fungal Drugs Market Share, By Infection Type, By Value, FY2017–FY2027F
Figure 26: Polyenes Anti-Fungal Drugs Market Share, By Route of Administration, By Value, FY2017–FY2027F
Figure 27: Polyenes Anti-Fungal Drugs Market Share, By End-User, By Value, FY2017–FY2027F
Figure 28: Polyenes Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, FY2017–FY2027F
Figure 29: Allylamines Anti-Fungal Drugs Market Size, By Value (USD Million), FY2017–FY2027F
Figure 30: Allylamines Anti-Fungal Drugs Market Share, By Indication, By Value, FY2017–FY2027F
Figure 31: Allylamines Anti-Fungal Drugs Market Share, By Infection Type, By Value, FY2017–FY2027F
Figure 32: Allylamines Anti-Fungal Drugs Market Share, By Route of Administration, By Value, FY2017–FY2027F
Figure 33: Allylamines Anti-Fungal Drugs Market Share, By End-User, By Value, FY2017–FY2027F
Figure 34: Allylamines Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, FY2017–FY2027F